A review of 42 studies finds a recurring association between lower circulating vitamin D and uterine fibroids, alongside laboratory evidence that vitamin D-related signaling can affect fibroid cells. But the studies have not established whether vitamin D status contributes to fibroids, reflects other factors, or changes as a result of the condition.

Godfrey Katamba and colleagues mapped clinical, molecular and genetic research on uterine leiomyomas, commonly called fibroids, in a scoping review published in PLOS ONE. The review covered 31 clinical studies, seven molecular studies and four genetic studies. Its purpose was to describe the range of evidence, rather than calculate a single combined effect or determine how reliable each study was. Source: PLOS ONE review

Most of the clinical studies reported lower blood concentrations of 25-hydroxyvitamin D, a measure of vitamin D status, among women with fibroids than among comparison groups. Several also found that lower levels were associated with greater fibroid size, volume or number. These are associations: most of the clinical research was observational, and relatively few studies followed participants over time.

One prospective study, involving 1,610 participants, offered a more cautious signal. It reported that levels of at least 30 nanograms per milliliter were associated with more fibroid loss. The estimated reduction in fibroid incidence was not statistically significant, however, so the result does not settle whether vitamin D status affects fibroid development.

The review also mapped findings from tissue and cell studies. Three of the seven molecular studies reported lower levels of the vitamin D receptor, or VDR, in fibroid tissue. Two found higher expression of CYP24A1, an enzyme involved in inactivating the active form of vitamin D. In two cell-culture studies, calcitriol or vitamin D3 suppressed Wnt/β-catenin signaling, which is involved in cell growth; one also reported suppression of mTOR signaling. These experiments suggest possible biological effects in cells, but they do not show that the same effects occur in people or change clinical outcomes.

The receptor is central to the open question: vitamin D signals through VDR, but the review found no included study that measured circulating vitamin D and VDR in the same participants and tested whether the receptor mediates or modifies the association with fibroids. The clinical pattern and the tissue findings therefore remain separate strands of evidence. They are compatible with a shared mechanism, but do not demonstrate one.

Genetic findings were also mixed. Across four studies, reported links between variants in VDR or vitamin D metabolism genes and fibroid susceptibility differed among populations. The review says the evidence is too limited and inconsistent to support a reliable, population-independent genetic conclusion.

Several features of the research make the overall pattern difficult to interpret. Fewer than half of the clinical studies adjusted for body mass index, and only one adjusted for ethnicity. Study designs, vitamin D measurement methods and definitions of deficiency also varied. Because most studies were cross-sectional or case-control, they cannot establish which came first. The review notes that fibroids or related inflammation could also affect measured vitamin D levels, leaving reverse causation possible.

The authors did not formally assess study quality or risk of bias, consistent with the review’s aim of mapping the literature. They conclude that the findings are hypothesis-generating, not evidence of a direct causal or therapeutic relationship. Prospective studies that measure vitamin D and tissue-level signals together, account for relevant confounders and track fibroid outcomes could help clarify how these lines of evidence fit together.